
The Most Dangerous Complications of HIV and AIDS
HIV weakens the immune system, making individuals susceptible to opportunistic infections (OIs), which can be life-threatening if the number of CD4 cells drops below 200 cells per cubic millimeter.
Common OIs associated with HIV include candidiasis, pneumonia, and herpes, as well as certain cancers such as Kaposi's sarcoma and lymphoma can also occur.
Following a prescribed drug regimen, getting vaccinated, practicing safe sex, and adopting healthy habits can prevent OIs, significantly improving the life expectancy and quality of life for people living with HIV.
Living with HIV can result in a weakened immune system. This makes the body more susceptible to a host of illnesses. Over time, HIV attacks the body's CD4 cells.
These cells play a critical role in maintaining a healthy immune system. People living with HIV can proactively reduce the likelihood of developing common, life-threatening illnesses by taking their prescribed daily medications and practicing healthy living habits.
What are HIV-related opportunistic infections?
Opportunistic infections (OIs) capitalize on weakened immune systems. In general, complications of HIV don't occur if the body's CD4 count is higher than 500 cells per cubic millimeter. Most life-threatening complications occur when the CD4 count drops below 200 cells per cubic millimeter.
OI illnesses may have little to no significant impact on a person with a healthy immune system. However, they can cause devastating effects for people living with HIV. OIs typically present when the CD4 count drops below 200 cells per cubic millimeter. They are considered stage 3 HIV (or AIDS-defining) conditions.
In general, a person living with HIV will not present with OIs if their CD4 count is above 500 cells per cubic millimeter.
The following 20 OIs have been defined by the Centers for Disease Control and Prevention as stage 3 HIV (or AIDS-defining) illnesses.
Infections common with HIV
Candidiasis. This is a common fungal infection that's also known as thrush. It can be treated with antifungal medications after a simple visual examination.
Coccidioidomycosis. This common fungal infection can lead to pneumonia if left untreated.
Cryptococcosis. This fungal infection often enters through the lungs. It can quickly spread to the brain, often leading to cryptococcal meningitis. Left untreated, this fungal infection is often fatal.
Cryptosporidiosis. This diarrheal disease often becomes chronic. It's characterized by severe diarrhea and abdominal cramping.
Cytomegalovirus. This common global virus affects most adults during their lifetime. It often presents with eye or gastrointestinal infections.
HIV-related encephalopathy. This is often referred to as HIV-related dementia. It can be defined as a degenerative brain condition that affects people with CD4 counts of less than 100.
Herpes simplex (chronic) and herpes zoster. Herpes simplex produces red, painful sores that appear on the mouth or genital area. Herpes zoster, or shingles, presents with painful blisters on skin surfaces. While there is no cure for either, medications are available to alleviate some symptoms.
Histoplasmosis. This environmental fungal infection is commonly treated with antibiotics.
Isosporiasis. This is a parasitic fungus. It develops when people drink or come into contact with contaminated food and water sources. It's currently treated with antiparasitic drugs.
Mycobacterium avium complex. This is a type of bacterial infection. It often presents in people with severely compromised immune systems (CD4 cell counts of less than 50). If these bacteria enter the bloodstream, it often results in death.
Pneumocystis carinii pneumonia (PCP). This OI is currently the leading cause of death in people living with HIV. Careful monitoring and antibiotic therapies are currently used to treat the person following diagnosis.
Chronic pneumonia. Pneumonia is an infection in one or both lungs. It can be caused by bacteria, viruses, or fungi.
Progressive multifocal leukoencephalopathy (PML). This neurological condition often affects people with CD4 cell counts below 200. While there is no current treatment for this disease, some response has been shown with antiretroviral therapies.
Toxoplasmosis. This parasitic infection commonly strikes people with CD4 cell counts below 200. Prophylaxis treatments are used as a preventive measure for people posting low CD4 cell counts.
Tuberculosis. This disease is most common in low-income areas of the world. It can be successfully treated in most cases if caught early.
Wasting syndrome (HIV-related). This OI causes a total weight loss of more than 10 percent of your normal body weight. Treatment involves dietary management and continued antiretroviral therapy.
Kaposi's sarcoma. This form of cancer often presents with either oral lesions or lesions covering the skin surfaces. Current treatments include radiation and chemotherapy to shrink the tumors. Antiretroviral therapy is also used to boost the body's CD4 cell count.
Lymphoma. A variety of cancers frequently present in people living with HIV. Treatment will vary based upon the person's cancer type and health condition.
Cervical cancer. Women living with HIV are at greater risk of developing cervical cancer. An impaired immune system presents challenges associated with treating this form of cancer.
Cancers common with HIV
If a person presents with one or more OIs, the disease will likely be categorized as stage 3 HIV (or AIDS), regardless of the person's current CD4 cell count. OIs are currently the leading cause of death for people living with HIV. However, antiretroviral therapies (HAART) and prophylaxis have shown promise in preventing these diseases, when taken as directed.
Staying healthy with HIV
Doctor-prescribed drug regimens and healthy daily living habits can greatly improve life expectancy as well as quality of life for people living with HIV. People living with HIV can proactively avoid many OIs by following these tips:
Follow a daily drug regimen that includes both antiretroviral therapies and prophylaxes (medications used to prevent disease).
Get vaccinated. Ask your doctor which vaccines you may need.
Use condoms consistently and correctly to avoid exposure to sexually transmitted infections.
Avoid illicit drug use and needle sharing.
Take extra precautions when working in high-exposure areas, such as day-care centers, prisons, healthcare facilities, and homeless centers.
Avoid raw or undercooked products and unpasteurized dairy products.
Wash your hands frequently when preparing foods.
Drink filtered water.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
UnitedHealth Group's (UNH) Healthcare Dominance: A Key Player in the Dogs of the Dow
UnitedHealth Group Incorporated (NYSE:UNH) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A senior healthcare professional giving advice to a patient in a clinic. The stock has dropped over 44% so far this year after reporting weaker-than-expected earnings in the first quarter. The company first reduced its full-year outlook and later chose to withdraw it entirely. Even with the underwhelming Q1 performance, UnitedHealth Group Incorporated (NYSE:UNH) still posted a 9.8% year-over-year increase in revenue, reaching $109.6 billion. It earned a profit of around $6.3 billion during the quarter and maintained a solid financial position, holding close to $34.3 billion in cash and cash equivalents, along with a debt level that remains manageable. The company has added 780,000 new members so far this year. Meanwhile, Optum Health still expects to provide value-based care to an additional 650,000 patients in 2025. In addition, UnitedHealth Group Incorporated (NYSE:UNH) generated $5.5 billion in operating cash flow during the quarter and returned $5 billion to investors through dividends and share repurchases. The company has been rewarding shareholders with growing dividends since 2011 and currently offers a quarterly dividend of $2.21 per share. The stock supports a dividend yield of 3.15%, as of July 26. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Forbes
2 hours ago
- Forbes
Changes In Prior Approval Coming To Traditional Medicare, Medicare Advantage
There were two major announcements recently regarding prior approval of treatments and services for Medicare beneficiaries. In most medical insurance, many treatments won't be covered unless it is approved first by the insurer. It's been a source of controversy for some time. Original Medicare hasn't required prior authorization of treatments and services, with a few exceptions. For most care, providers and the patient agree on a treatment. After the treatment, paperwork for approval and payment is submitted to Medicare. Medicare recently announced a new model program that will test pre-approval. The voluntary model program will test pre-approval for some services and treatments, according to a recent announcement from the Center for Innovation of the Centers for Medicare and Medicaid Services. The model program is seeking medical providers to volunteer for the program from Jan. 1, 2026 through Dec. 31, 2031. The model will be restricted to New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. Providers who volunteer and are accepted will agree to seek prior authorization for 17 items and services, including skin substitutes, deep brain stimulation for Parkinson's Disease, impotence treatment, and arthroscopy for knee osteoarthritis. A provider who volunteers for the program can choose not to seek prior approval for a case. There will be a post-treatment review of the case, and the provider will risk not being paid by Medicare for the treatment. CMS initiated the program and selected the services to be covered because of a series of reports showing waste, fraud or abuse in certain areas. For example, Medicare spent up to $5.8 billion in 2022 on unnecessary or inappropriate services that had no clinical benefit, according to the Medicare Payment Advisory Commission. Under the model, providers will submit the same information they currently submit for payment approval after a service is provided to a beneficiary. The difference is that under the model, the information will be submitted earlier and the provider will wait for approval before performing the services. CMS will select companies to receive and review the prior authorizations. It expects that they will use artificial intelligence and other tools in addition to medical professionals to review the submissions. The companies will be paid based on the extent to which they saved the government money by stopping unnecessary services. CMS said it will manage the program to avoid adverse impact on beneficiaries and providers. There was other news about pre-approval, this time involving Medicare Advantage plans. Pre-approval in Medicare Advantage plans has been controversial recently. There have been a number of recent reports and studies that found the authorization process was delaying treatment or causing patients to abandon treatment plans. Other reports indicated that a high percentage of treatments that initially were denied coverage eventually were approved if the patients or their providers appealed the than 50 major insurers who sponsor many types of insurance plans announced that they will voluntarily streamline prior authorization of treatments and services in all insurance markets, including Medicare Advantage plans. The insurers say they plan to have the new process in place by Jan. 1, 2027.
Yahoo
3 hours ago
- Yahoo
Labcorp Holdings Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Labcorp Holdings (NYSE:LH) Second Quarter 2025 Results Key Financial Results Revenue: US$3.53b (up 9.5% from 2Q 2024). Net income: US$237.9m (up 16% from 2Q 2024). Profit margin: 6.7% (up from 6.4% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: US$2.85 (up from US$2.44 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Labcorp Holdings Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 12%. Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are up 8.7% from a week ago. Risk Analysis You should learn about the 2 warning signs we've spotted with Labcorp Holdings. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.